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ABSTRACT
Flexible bronchoscopy and endobronchial ultrasound guided transbronchial needle aspiration
(EBUS-TBNA) are the pulmonologists´ basic procedures for the biopsy of suspicious lung lesions. If
inconclusive, other guiding-modalities for tissue sampling are needed, computed tomography
performed by a radiologist, or – if available – radial EBUS or electromagnetic navigation biopsy.
We wanted to investigate if same-day X-ray fluoroscopy-guided transthoracic fine-needle
aspiration biopsy (F-TTNAB) performed by the pulmonologist immediately after bronchoscopy
and EBUS is a feasible alternative.
We retrospectively identified consecutive patients in whom F-TTNAB followed a bronchoscopy
and EBUS in the same séance. Patients in whom the suspicion of malignancy was invalidated after
complete work up were followed for six months to identify false-negative cases.
In total 125 patients underwent triple approach (bronchoscopy, EBUS and F-TTNAB) during the
same séance. Malignancy was diagnosed in 86 (69%), and 77 of these (90%) were primary lung
cancers. The diagnostic yield of F-TTNAB for malignancy was 77%, and sensitivity was 90%.
Pneumothorax occurred in 35 (28%) patients, and was administered with pleural drainage in 22
(18% of all patients). No cases of prolonged haemoptysis were observed. The risk of pneu-
mothorax differed insignificantly with lesion size ≤2.0 cm (27%) versus >2.0 cm (29%).
We conclude that it is feasible for pulmonologist to perform F-TTNAB immediately after
endoscopy as a combined triple approach in a fast-track workup of suspected lung cancer.
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Invasive procedures represent a cornerstone in the diag-
nostic approach to patients with lung lesions. Distinction
between a malignant and non-malignant cause of the
lesion is fundamental for treatment planning. Therefore,
the provision of a biopsy is essential. Centrally located lung
lesions can be biopsied with the use of bronchoscopy or
endosonography [1], which is traditionally performed by
the pulmonologist [2]. Peripheral lesions can be biopsied
endoscopically guided by radial endobronchial ultrasound
(R-EBUS) [3] or electromagnetic navigation bronchoscopy
(ENB) [4], or transthoracically guided by ultrasound [5] or
computed tomography (CT) [6]. There is no clear correla-
tion between diagnostic yield, complication risk or costs:
using ENB results in fewer complications but increased
costs compared to CT-guided biopsy [7].
CT-guided biopsy often lies in the hands of the
radiologist [8,9]. The radiologist also performs per-
cutaneous lung biopsy guided by conventional X-ray
fluoroscopy, which is a valuable alternative to CT
guided biopsy [10]. Most bronchoscopists are famil-
iar with fluroscopy-guided bronchoscopy [11].
However, the feasibility of fluoroscopy-guided trans-
thoracic needle aspiration biopsy (F-TTNAB) in the
hands of the pulmonologist has not been described
in the literature before except for a single paper from
our group [12].
Objectives
On this background we decided to
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(1) Determine the diagnostic yield and complica-
tion rate of F-TTNAB in the hands of the
pulmonologist.
(2) To examine if it is feasible to perform F-TTNAB
in combination with bronchoscopy and endo-
bronchial ultrasound transbronchial needle
aspiration (EBUS-TBNA).
Materials and methods
We retrospectively searched in the hospital’s electronical
database for patients that underwent F-TTNAB,
bronchoscopy and EBUS-TBNA at the same day from
1 September 2012 to 31December 2013 in our pulmonary
department because of suspected lung cancer. All patients
had an initial evaluation with a medical history and
physical examination, chest R ray, blood tests and elec-
trocardiogram. Computer tomography (CT) scan with
contrast enhancement and/or positron emission tomo-
graphy- computer tomography (PET-CT) was per-
formed. Lesion size, defined as the maximum axial
diameter, location and distance to pleura was measured
on CT images obtained on lung windows. Oral and
written information concerning all procedures and pos-
sible complications were given to the patient and
informed consent obtained.
Bronchoscopy and EBUS-TBNA were performed
under conscious sedation by the administration of
midazolam and fentanyl intravenously in an ambula-
tory setting. Bronchoscopy was performed in all
patients, since the surgeons demand an inspection of
the bronchial tree in all patients who may be potential
candidates for surgery. The patients received additional
oxygen during the procedures. Oxygen saturation and
pulse were monitored. The bronchoscopy was only
supplemented with EBUS-TBNA if indicated according
to the European Guidelines [1] (for example abnormal
hilar or mediastinal lymph nodes/centrally located lung
tumor). Bronchoscopy was performed with an
Olympus BF-1T180 (Olympus XBF-UC40P; Olympus
Medical Systems Europe Ltd., Hamburg, Germany),
and EBUS-TBNA was performed with a flexible ultra-
sound bronchoscope (Olympus XBF-UC40P; Olympus
Medical Systems Europe Ltd., Hamburg, Germany)
using a 22-G Olympus NA-200C needle with biopsy
sampling according to guidelines [13].
If no lung tumor or no abnormal lymph nodes were
demonstrated by bronchoscopy or EBUS, it was consid-
ered unlikely that endoscopy would provide a conclusive
diagnosis. Rapid onsite evaluation (ROSE) was not acces-
sible. In these cases F-TTNABwas performed immediately
(Figure 1). The patient was placed in an appropriate supine
position depending of the location of the lung lesion,
which was localized in two planes with X ray fluoroscopy
and the preferred route of the biopsy needle was chosen.
X ray fluoroscopy was performed using a C-arm Ziehm
exposcop 8000 (Ziehm GmBH, Nürnberg, Germany). The
skin entry site was sterilized with standardized antiseptic
solution and the cutaneous and subcutaneous tissue infil-
trated with lidocaine up to a maximum dose of 20 ml of
a 2% solution. Firstly, during lateral fluoroscopy and sus-
pended patient respiration, a 7.5 mm guiding needle
(Super 4 needle, (BD Angiomed GmBH, Karlsruhe,
Germany) was placed adjacent to the lesion. Secondly,
aspiration biopsies were obtained using a 220 mm Chiba
22G needle (BD Angiomed GmBH, Karlsruhe, Germany)
via the guiding needle during shallow patient breathing
and lateral fluoroscopy with at least two needle passes [14].
Suction was applied to the Chiba-needle by a 10 mL syr-
inge, and aspirated material was transferred to slides and
a designated container for cell block preparation. The
biopsy procedure was followed by observation for at least
60 minutes with measurements of respiration frequency,
peripheral oxygen saturation, blood pressure, pulse. At
60 minutes, all patients underwent a standing, full inspira-
tion chest X ray.
Performance status was described using the The
Eastern Cooperative Oncology Group (ECOG) score,
and comorbidity was summarized using the Charlson´s
index of comorbidity [8].
Standard of reference
Samples with malignant cells were considered true
positive. For samples with non-malignant diagnoses at
cytopathological evaluation, the results were consid-
ered true negative if the results were verified by at
least six months follow up (clinical course possibly
supplemented with computed tomography (CT).
Diagnostic yield was defined as the number of sam-
ples in which F-TTNAB provided a specific diagnosis
(malignant or non-malignant) relative to the total
number of F-TTNAB samples performed. Sensitivity
was defined as the number of samples in which
F-TTNAB provided a diagnosis of any malignancy
relative to the total number of targeted lung lesions
that turned out to be malignant. Patients in whom the
suspicion of lung cancer was invalidated after complete
work up were followed for six months to identify false-
negative cases.
Statistics
Statistical analysis was performed using SPSS Statistics
software for Windows, v.24 (IBM Corp., Armonk, N.Y.,
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USA). Categorical variables were compared using
Pearson’s Chi2-test or Fisher’s exact test (when expected
n < 5 for any variable). Mann-Whitney U-test was
applied for continuous variables. Results were collected
in tables where continuous data were expressed as med-
ian (range) and binary data as percentages. Results were
considered significant when p < 0.05.
Ethics
The study was a retrospective observational study with-
out randomization or intervention in the treatment of
the patients. These types of studies are exempt from
approval by the local Research Ethics Committee
according to Danish legislation. Patient data were
anonymously collected, and The Danish Data
Protection Agency approved the study.
Results
We identified 125 patients who underwent F-TTNAB
after bronchoscopy and/or EBUS-TBNA. Baseline
characteristics are presented in Table 1. Table 2
shows that totally 86 patients (69%) received a final
diagnosis of malignancy. F-TTNAB was conclusive in
96 patients, (overall diagnostic yield 77%). Of the
remaining patients, two patients had a conclusive
EBUS-TBNA, 23 underwent re-sampling, and four
patients entered a CT control follow-up program.
Sensitivity for a diagnosis of malignancy was 90% (71
cases diagnosed by F-TTNAB).
Figure 1. a) PET-CT showing a peripheral solid lesion in the anterior part of right upper lobe without pleural contact or bronchus
sign (arrow). (b) With the patient in supine position, the operator locates the lesion in the anterior-posterior (A-P) projection with
the C-arm with on-time fluoroscopic images on the screen.. (c) The borders of the lesion are marked on the skin with a filt pen and
a metallic ruler. (d) Fine-needle aspiration with a Chiba needle via a guiding needle. The position of the needle tip can be checked
with the C-arm in any angle different from the A-P-projection.
The patient gave full informed consent to present photos with the aim to enhance learning.
Table 1. Baseline characteristics and radiological features
(n = 125) .
Female, n (%) 63 (50%)
Age, median years (range) 69 (41–87)
ECOG performance status, median (range) 0 (0–3)
Charlson’s index of Comorbidity, median (range) 1 (0–8)
Pack years, median (range) 38 (0–100)
Tumour location, n (%)
Right upper lobe 41 (33%)
Right middle lobe 8 (6%)
Right lower lobe 16 (13%)
Left upper lobe 41 (33%)
Left lower lobe 17 (14%)
Tumour size (mm), median diameter (range) 25 (9–72)
Tumour distance from pleura (mm), median (range) 22 (0–121)
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Pneumothorax was by far the most common com-
plication, and observed in 35 patients (28%). A pleural
pig tail catheter was necessary in 22 (18% of total; 62%
of patients with pneumothorax).
No cases of recurrent haemoptysis or pain were
observed.
Lesions with an average diameter of ≤2 cm were not
associated with a higher risk of pneumothorax (27%)
compared with lesions >2 cm (29%; p > 0.8, Chi2-test).
Discussion
It is important to diagnose patients suspected of lung
cancer as quickly as possible [1,15]. Firstly, a lung
cancer can advance to a higher stage if curative
intended treatment is delayed. Secondly, the waiting
time for a diagnosis is a mental strain for both the
patient and the patient´s relatives. Thirdly, individual
and societal costs increase with number of visits [16].
Bronchoscopy and EBUS-TBNA are basic proce-
dures in the investigation of patients with lung lesions.
If these techniques do not give access to the lung
lesion, and a diagnosis is not obtained from extrapul-
monary lesions, the next step may be referral to
a radiologist for a CT guided lung biopsy later. We
investigated if F-TTNAB performed by the pulmonol-
ogist in combination with bronchoscopy and EBUS-
TBNA (a triple approach) could be an alternative. The
principles of the triple approach are demonstrated in
Figure 2.
Overall, F-TTNAB was able to establish a diagnosis
in approximately three out of four patients with
a malignant diagnosis, which is comparable and not
significantly different from the results of previous stu-
dies assessing percutaneous biopsy of the lung [9].
The most common complication to CT guided lung
biopsy is pneumothorax, which occurs in 0–61% of the
cases [9]. Between 3.3% and 15% of all patients will
require a chest drain [9]. Yeow et al found a risk for
pneumothorax and hemoptysis of 23% and 4%, respec-
tively, in a cohort of 660 consecutive procedures [17].
The risk for pneumothorax was increased risk when
the lesion diameter was ≤ 2 centimeters [17]. In our
study, pneumothorax risk was 28% and 18% of all
patients required a chest drain, thus slightly increased.
We did not find an increased risk with tumor size ≤ 2
centimeters, and we observed no cases of protracted
haemoptysis. Unfortunately, there are no systematic
reports in the literature concerning the risk of pneu-
mothorax and chest tube requiring pneumothorax in
connection with F-TTNAB.
It could be argued, that non-diagnostic broncho-
scopy and EBUS should not be followed by F-TTNAB
but by more modern sampling guided by electromag-
netic navigation bronchoscopy (ENB) and radial ultra-
sound probe [1,13]. However, in many centres –
especially in non-Western countries – these techniques
are not available due to the substantial costs for single-
purpose equipment. Fluoroscopy is used in several
disciplines of medicine and is readily available even in
low-income countries. The sampling of peripheral lung
lesions guided by CT or fluoroscopy normally requires
referral to a radiologist [16], which will cause a delay in
the diagnostic workup. A combined, same-day invasive
triple approach aiming at both diagnosis and staging
will speed up the process. The equipment for fluoro-
scopy is routinely available in the operating room of
the pulmonologist, since it is used when performing
transbronchial lung biopsies [13].
A randomized study comparing a) the triple approach
with b) FB and EBUS followed by referral of the patient to
a radiologist for percutaneous lung biopsy seems redun-
dant if the purpose were to investigate if the former
Table 2. F-TTNAB biopsy results (n = 125).
Primary lung cancer, n (%) 77 (62%)
Adenocarcinoma 41 (33%)
Squamous cell carcinoma 21 (17%)
Large-cell neuroendocrine carcinoma 2 (2%)
Non-small cell lung cancer, unspecified 8 (6%)
Small cell lung cancer 4 (3%)
Carcinoid 1 (1%)
Metastasis from extrapulmonary cancer, n (%) 9 (6%)
Non-malignant, n (%) 39 (31%)
Infection 0
Figure 2. Schematic drawing of the principles of the triple
approach. EBUS: endobronchial ultrasound, F-TTNAB: fluoro-
scopy-guided transthoracic fine-needle aspiration biopsy.
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approach decreases the waiting time for a lung biopsy. Of
course, it could be argued that suspicious lung lesions
should be removed by the surgeons without waiting for
a malignant biopsy. However, this is not recommended as
a suspicious lesion might be for example pneumonia or
other localized inflammation [18]. One could claim that
F-TTNAB could appear to be superfluous in selected
cases where EBUS-TBNA unexpected reveals diagnostic
material from the mediastinum or the hilar regions. This
was the case in two of our 125 patients (1.6%). We think
that this risk of performing an F-TTNAB procedure, that
retrospectively shows up to be superfluous, is acceptable
and relatively small.
Though inclusion in this study was consecutive,
a limitation is a selection bias due to the retrospective
design. Subsequent studies should include larger
cohorts in a prospective multi-centre design including
exclusively consecutive patients. A strength to this
study is that it shows the results of F-TTNAB as an
integrated part of the triple approach in everyday clin-
ical workup, supporting our findings in another [17].
There are no guidelines or standardized training
programs for learning F-TTNAB. Prior to the imple-
mentation of the procedure, the physicians were
experienced in other transthoracic procedures (e.g.
pleural drainage and medical thoracoscopy) The edu-
cation in the F-TTNAB was based on traditional
apprenticeship training.
We conclude that it is feasible to perform F-TTNAB
immediately after a non-diagnostic FB and EBUS-TBNA
in the investigation of patients with suspicious lung
lesions.
Disclosure statement
No potential conflict of interest was reported by the authors.
Notes on contributors
Jatinder Singh Sidhu is a specialist registrar in respiratory
medicine with special interest in interventional pulmonology.
Geir Salte is a young doctor with interest in respiratory
medicine.
Ida Skovgaard Christiansen is a resident doctor and PhD-
fellow. She has an interest in interventional pulmonology and
pathology.
Therese Maria Henriette Naur is a resident doctor. She has
an interest in interventional pulmonology, oncology and
simulation based training, and she has published several
papers in these areas.
Asbjørn Høegholm is a consultant in internal and respiratory
medicine and particularly interested in invasive procedures
for the diagnosis and staging of suspected cancer in lungs or
pleura, and member of the Danish Lung Cancer Group
steering committee working for improved survival in lung
cancer.
Paul Frost Clementsen is a consultant in pulmonary medi-
cine and particularly interested in simulator based training,
supervised training programs and assessment of competence
in endoscopic ultrasonography and fine-needle aspiration
and other invasive procedures for the diagnosis and staging
of lung cancer.
Uffe Bodtger is a consultant in respiratory medicine and
particularly interested in invasive and non-invasive proce-
dures for the diagnosis suspected cancer in lungs or pleura,
as well as non-pharmacological treatment in COPD or
asthma.
ORCID
Ida Skovgaard Christiansen http://orcid.org/0000-0001-
6115-2890




[1] Vilmann P, Clementsen PF, Colella S, et al. Combined
endobronchial and esophageal endosonography for the
diagnosis and staging of lung cancer. A clinical guide-
line by the European Society of Gastrointestinal
Endoscopy (ESGE), European Respiratory Society
(ERS) and European Society of Thoracic Surgeons
(ESTS). Eur Respir J. 2015;46(1):40–60.
[2] Herth F, Shah P, Gompelmann D. Interventional
pulmonology. ERS monography. European
Respiratory Society; 2017. ISBN 978-1-84984-091-0.
[3] Ali MS, Trick W, Mba BI, et al. Radial endobronchial
ultrasound for the diagnosis of peripheral pulmonary
lesions: A systematic review and meta-analysis.
Respirology. 2017 Apr;22(3):443–453.
[4] Folch EE, Pritchett MA, Nead MA, et al.
Electromagnetic navigation bronchoscopy for peripheral
pulmonary lesions: one-year results of the prospective,
multicenter NAVIGATE study. J Thorac Oncol. 2019
Mar;14(3):445–458.
[5] Laursen CB, Naur TM, Bodtger U, et al. Ultrasound-
guided lung biopsy in the hands of respiratory physicians:
diagnostic yield and complications in 215 consecutive
patients in three centers. J Bronchology Interv Pulmonol.
2016;23(3):220–228.
[6] Ashraf H, Kragh-Andersen S, Naqibullah M, et al.
Computer tomography lung biopsy using interactive
breathhold control. A randomized study. Ann Transl
Med. 2017;5(12):253.
[7] Dale CR, Madtes DK, Fan VS, et al. Navigational broncho-
scopy with biopsy versus computed tomography-guided
biopsy for the diagnosis of a solitary pulmonary nodule: a
cost-consequences analysis. J Bronchology Interv
Pulmonol. 2012 Oct;19(4):294–303.
EUROPEAN CLINICAL RESPIRATORY JOURNAL 5
[8] Tavare AN, Hare SS, Miller FNA, et al. A survey of UK
percutaneous lung biopsy practice: current practices in the
era of early detection, oncogenetic profiling, and targeted
treatments. Clin Radiol. 2018 Jun 16;73:800–809.
[9] Manhire A, Charig M, Clelland C, et al. Guidelines for
radiologically guided lung biopsy. Thorax. 2003;58
(11):920–936.
[10] Kurban LA, Gomersall L,Weir J, et al. Fluoroscopy-guided
percutaneous lung biopsy: a valuable alternative to com-
puted tomography. Acta Radiol. 2009;49(8):876–882.
[11] Georgia Hardavella and Jeremy George. Breathe (Sheff).
Interventional bronchoscopy in the management of
thoracic malignancy. 2015 Sep;11(3):202–212.
[12] Madsen KR, Høegholm A, Bodtger U. Accuracy and
consequences of same-day, invasive lung cancer workup
- a retrospective study in patients treated with surgical
resection. Eur Clin Respir J. 2016;Nov(3):32590.
[13] Eberhardt R, Anantham D, Ernst A, et al. Multimodality
bronchoscopic diagnosis of peripheral lung lesions:
a randomized controlled trial. Am J Respir Crit Care
Med. 2007;176(1):36–41.
[14] Khouri NF, Stitik PF, Erozan YS, et al. Transthoracic
needle aspiration biopsy of benign and malignant lung
lesions. Am J Radiol. 1985;144:281–288.
[15] Gaga M, Powell CA, Schraufnagel DE, et al. An official
American thoracic society/European respiratory society
statement: the role of the pulmonologist in the diagnosis
and management of lung cancer. Am J Respir Crit Care
Med. 2013 Aug 15;188(4):503–507.
[16] Jacobs P,Hall EM. Estimating the cost of outpatient hospital
care. Healthcare Manage Forum. 1995 Winter;8(4):36–38.
[17] Yeow KM, Su IH, Pan KT, et al. Multivariate analysis of
660 CT-guided coaxial cutting needle lung biopsies.
Chest. 2004;126(3):748–754.
[18] Callister MJ, Baldwin DR, Akram AR, et al. BTS
guidelines for the investigation and management
of pulmonary nodules. Thorax. 2015 August;70
(Supplement 2):ii1–ii54.
6 J. S. SIDHU ET AL.
